India Intravenous Solution Market

India Intravenous Solution Market Size and Share:

The India intravenous solution market size was valued at USD 1.90 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 2.96 Billion by 2033, exhibiting a CAGR of 4.81% from 2025-2033. Central India dominates the market, holding 35.00% of the market share. The market is witnessing significant growth mainly driven by rising medical procedures, chronic illness cases, and improved healthcare access. In line with this, demand for TPN and non-PVC bags is increasing, contributing significantly to the India intravenous solution market share.

Rising cases of dehydration, chronic illnesses, and surgeries in hospitals are fueling demand for intravenous (IV) solutions across India. An expanding geriatric population and higher incidence of gastrointestinal disorders have increased the use of fluid replacement therapies. According to the data published by UNFPA, India's elderly population (aged 60 and above) is set to rise from 153 Million to 347 Million by 2050. Moreover, government focus on improving rural healthcare infrastructure and growing medical tourism are further pushing hospitals and clinics to maintain a steady supply of IV fluids, especially in states with high patient influx.

Another major driver is the surge in demand for single-use IV bags and parenteral nutrition solutions driven by infection control awareness. The pharmaceutical industry is also scaling up IV drug production, supported by increased approvals of injectable formulations. For instance, in January 2023, Glenmark Pharmaceuticals launched AKYNZEO I.V. in India, a novel intravenous formulation for preventing chemotherapy-induced nausea and vomiting (CINV). Administered as a single infusion before chemotherapy, it combines fosnetupitant and palonosetron, addressing both acute and delayed CINV phases, improving patient compliance and reducing the need for multiple medications. Alongside, private investments in specialty and multi-specialty hospitals, and expanding health insurance coverage, are contributing to wider accessibility and usage of intravenous therapy across both public and private care segments.

India Intravenous Solution Market Trends:

Growth in Parenteral Nutrition Demand

The use of total parenteral nutrition (TPN) is rising in India’s critical care and neonatal settings due to its effectiveness in supporting patients unable to consume food orally or enterally. TPN provides essential nutrients directly into the bloodstream, helping stabilize patients with gastrointestinal disorders, premature infants, or those recovering from major surgeries. Hospitals are expanding ICU capacities and adopting standardized nutrition protocols, further increasing TPN usage. Demand is also rising from oncology departments, where patients often require specialized nutritional support. For instance, in November 2023, Sanjivani Paranteral announced its partnership with Hindustan Antibiotics to manufacture IV formulations and IV sets, backed by a Rs 50 crore investment. A new manufacturing facility will be established in Pune, with production expected to begin in Q3 FY25, enhancing healthcare delivery in India through improved pharmaceutical standards.

Shift Toward Premixed and Ready-to-Use IV Solutions

Hospitals across India are favoring premixed and ready-to-use IV solutions to enhance operational efficiency and improve patient safety. These prefilled formulations reduce the need for manual preparation, thereby minimizing the risk of contamination and dosage inaccuracies. They are particularly useful in emergency care, where time-sensitive interventions are critical. With the growing emphasis on standardized care and the rise of multi-specialty hospitals, the market for ready-to-use IV solutions is expected to expand steadily over the next few years.

Rising Adoption of Non-PVC IV Bags

Healthcare providers in India are increasingly shifting to non-PVC IV bags due to concerns over DEHP, a plasticizer used in traditional PVC bags that may leach harmful chemicals into solutions. This shift is driven by a greater focus on patient safety, particularly for vulnerable groups like neonates, cancer patients, and those requiring long-term IV therapy. Manufacturers are responding by introducing eco-friendly, DEHP-free alternatives. The trend is likely to strengthen with tightening regulatory standards and hospital procurement guidelines. These trends are creating a positive India intravenous solution market outlook.

India Intravenous Solution Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the India intravenous solution market, along with forecasts at the regional levels from 2025-2033. The market has been categorized based on type and nutrients.

Analysis by Type:

• Partial Parenteral Nutrition
• Total Parenteral Nutrition

Total parenteral nutrition stands as the largest type in 2024, holding around 56.7% of the market. Total parenteral nutrition (TPN) holds the largest share in India’s intravenous solution market due to its critical role in managing malnourished patients, especially in ICUs, oncology wards, and neonatal care. TPN delivers essential nutrients intravenously when oral or enteral feeding isn't feasible. Rising awareness about clinical nutrition, increased incidence of chronic diseases, and expanding intensive care infrastructure are fueling its demand. Hospitals are prioritizing TPN for better recovery outcomes, making it a dominant segment in therapeutic IV solutions.

Analysis by Nutrients:

• Carbohydrates
• Salts and Electrolytes
• Minerals
• Vitamins
• Amino Acids

Salts and electrolytes lead the market with around 42.7% of market share in 2024. Salts and electrolytes account for the largest share of India’s intravenous solution market, driven by their routine use in treating dehydration, electrolyte imbalances, and surgical recovery. Solutions like sodium chloride, ringer lactate, and dextrose saline are widely used across primary healthcare centers and tertiary hospitals. Their cost-effectiveness, easy availability, and broad applicability in emergency and general care settings support high demand. As hospital admissions rise, especially for trauma and gastrointestinal issues, this segment continues to lead the market.

Regional Analysis:

• North India
• West and Central India
• South India
• East India

In 2024, West and Central India accounted for the largest market share of over 35.0%. West and Central India represent the largest regional markets for intravenous solutions due to the high concentration of healthcare facilities, pharmaceutical hubs, and patient volume in states like Maharashtra, Gujarat, and Madhya Pradesh. These regions benefit from strong distribution networks and advanced hospital infrastructure. Urban centers with rising surgical procedures and chronic disease management needs further boost demand. Additionally, the presence of major IV solution manufacturers in these regions supports efficient supply and consistent market growth.

Competitive Landscape:

The India intravenous solution market is moderately fragmented, with several domestic and regional players competing on price, quality, and distribution reach. Companies are investing in advanced manufacturing facilities to meet rising demand and comply with quality standards set by regulatory authorities. There is a growing focus on expanding product portfolios to include non-PVC bags, TPN formulations, and specialty infusion products. Strategic collaborations with hospitals, supply chain optimization, and regional penetration into tier II and III cities are shaping competition. Innovation in packaging, infection control features, and customization for specific patient needs are also influencing competitive positioning in the market.

The report provides a comprehensive analysis of the competitive landscape in the India intravenous solution market with detailed profiles of all major companies, including:

• Piramal Enterprises Limited
• Troikaa Pharmaceuticals Ltd
• Baxter India (Baxter International Inc.)
• Fresenius Kabi India Pvt. Ltd. (Fresenius SE & Co. KGaA)
• Amanta Healthcare Ltd.
• Otsuka Pharmaceutical India Pvt. Ltd.
• Abaris Healthcare Pvt. Ltd

Latest News and Developments:

• February 2025: Aakash Healthcare launched North India's first dedicated Vein Clinic in collaboration with Medtronic, offering advanced, minimally invasive treatments for varicose veins. The clinic aimed to provide comprehensive vein care, addressing chronic pain and complications. The collaboration strengthened vascular treatment options, promoting awareness and better patient outcomes for vein-related issues.

India Intravenous Solution Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the India intravenous solution market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the India intravenous solution market.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the India intravenous solution industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.